Equities analysts expect Cellectis SA (NASDAQ:CLLS) to post $3.87 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Cellectis’ earnings, with the lowest sales estimate coming in at $2.23 million and the highest estimate coming in at $5.50 million. Cellectis reported sales of $3.08 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 25.6%. The business is scheduled to announce its next quarterly earnings report on Monday, March 9th.
On average, analysts expect that Cellectis will report full year sales of $18.43 million for the current financial year, with estimates ranging from $14.40 million to $22.10 million. For the next fiscal year, analysts anticipate that the company will report sales of $78.27 million, with estimates ranging from $15.00 million to $134.60 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Cellectis.
CLLS has been the subject of several research analyst reports. BTIG Research upped their price target on shares of Cellectis from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Wednesday. Nomura restated a “buy” rating and set a $73.00 price target on shares of Cellectis in a research report on Monday, December 16th. William Blair restated a “buy” rating on shares of Cellectis in a research report on Monday, January 13th. Zacks Investment Research upgraded shares of Cellectis from a “hold” rating to a “strong-buy” rating and set a $22.00 price target for the company in a research report on Friday. Finally, BidaskClub downgraded shares of Cellectis from a “buy” rating to a “hold” rating in a research report on Tuesday. Four research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $37.67.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CLLS. Citigroup Inc. raised its position in shares of Cellectis by 136.3% during the 4th quarter. Citigroup Inc. now owns 1,531 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 883 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Cellectis by 103.2% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,831 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 930 shares during the last quarter. Lindbrook Capital LLC raised its position in shares of Cellectis by 164.6% during the 4th quarter. Lindbrook Capital LLC now owns 2,008 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 1,249 shares during the last quarter. Bank of America Corp DE raised its position in shares of Cellectis by 74.3% during the 4th quarter. Bank of America Corp DE now owns 5,005 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 2,133 shares during the last quarter. Finally, Granite Point Capital Management L.P. acquired a new stake in Cellectis in the 4th quarter valued at about $171,000. Hedge funds and other institutional investors own 30.83% of the company’s stock.
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
See Also: Why do commodities matter?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.